Skip to main content
PCI Biotech Holding logo

PCI Biotech Holding — Investor Relations & Filings

Ticker · PCIB ISIN · NO0010405640 LEI · 5967007LIEEXZXFIGG77 OL Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2015-08-18 Report Publication Anno…
Country NO Norway
Listing OL PCIB

About PCI Biotech Holding

https://www.pcibiotech.no/

PCI Biotech Holding is a biopharmaceutical company developing therapeutic products based on its proprietary Photochemical Internalization (PCI) technology. This platform is a drug and nucleic acid delivery system designed to enhance the intracellular delivery of therapeutic molecules. The company's development programs are focused on applications in immunotherapy, dermatology, and bioprocessing for the manufacturing of viral vectors. A primary therapeutic area for the technology is cancer, where it aims to improve the efficacy of novel and existing treatments.

Recent filings

Filing Released Lang Actions
PCI Biotech: Second quarter and first half year 2015 results
Report Publication Announcement Classification · 98% confidence The document is very short (611 characters) and explicitly states: 'Please find the financial report and presentation for second quarter and first half 2015 enclosed.' It announces the availability of the results for the second quarter and first half of the year, which typically corresponds to an Interim/Quarterly Report (IR). However, based on the 'MENU VS MEAL' rule, since this document is merely an announcement stating that the report is enclosed/published, and it is not the comprehensive report itself, it should be classified as a Report Publication Announcement (RPA). The content is an announcement about the release of the Q2/H1 2015 results.
2015-08-18 English
PCI Biotech: Successful completion of the third dose cohort in the study for patients with inoperable bile duct cancer
Legal Proceedings Report Classification · 99% confidence The document is a press release from PCI Biotech dated August 18, 2015, announcing the successful completion of a dose cohort in a Phase I/II clinical study for bile duct cancer treatment. It details clinical progress, committee recommendations, and company background. This type of announcement, focusing on operational or clinical trial updates that are not full financial reports (10-K, IR) or formal earnings releases (ER), typically falls under general regulatory announcements or investor relations updates. Since it is a specific operational update that doesn't fit the definitions for ER, CT, LTR, or CAP, and it is not a formal financial report, it is best classified as a general Regulatory Filing (RNS) as per the provided definitions, which serves as a fallback for miscellaneous regulatory announcements. The document length is short (3547 chars), but it is providing substantive news, not just announcing another report, so RPA is less appropriate than RNS for this type of operational news release.
2015-08-18 English
PCI Biotech: Presentation of second quarter and first-half year 2015 results
Report Publication Announcement Classification · 98% confidence The document text is very short (750 characters) and explicitly states that PCI Biotech 'invites to a presentation' of its 'second quarter and first-half year 2015 report' on a specific future date (August 18, 2015). This is an announcement about an upcoming event where results will be discussed, rather than the full report (IR) or the transcript of the call (CT). Since it is an announcement regarding the publication/presentation of financial results, it fits best under Report Publication Announcement (RPA), which covers announcements about the timing or release of company reports.
2015-08-11 English
PCI Biotech: Mandatory notification of trade
Director's Dealing Classification · 100% confidence The document explicitly states it is a 'Mandatory notification of trade' concerning a purchase of shares by a 'primary insider and Chief Business Development Officer, Gaël L'Hévéder'. This directly relates to reporting personal share transactions by company directors and executives (insider trades). This aligns perfectly with the definition for Director's Dealing (DIRS). The document is short and contains specific transaction details, confirming it is the notification itself, not an announcement of a report.
2015-06-30 English
PCI Biotech: Mandatory notification of trade
Director's Dealing Classification · 100% confidence The document explicitly states 'Mandatory notification of trade' and details share purchases made by primary insiders (CEO, CFO, CSO) along with their resulting total holdings of shares and unexercised options. This directly corresponds to the definition of Director's Dealing (insider trades). The filing type code DIRS is the correct classification.
2015-06-08 English
PCI Biotech: Update on the ENHANCE study
Regulatory Filings Classification · 99% confidence The document is a short announcement from PCI Biotech dated June 3, 2015, providing an update on a specific clinical study (ENHANCE study) and outlining strategic shifts, including stopping one study and focusing resources on others (bile duct cancer and immunotherapy). It details clinical and strategic considerations for this change. This type of operational and strategic update, which is not a formal financial report (like 10-K or IR), nor a management change (MANG), nor a dividend announcement (DIV), nor a specific regulatory filing form, fits best under a general regulatory announcement or update category. Given the context of a company updating the market on its clinical pipeline and strategic direction, it is most appropriately classified as a general Regulatory Filing (RNS), as it is a required disclosure to the market (implied by the reference to the Norwegian Securities Trading Act) that doesn't fit the more specific operational codes like ER, CT, or CAP. It is not a Report Publication Announcement (RPA) because it is providing substantive operational news, not just announcing the publication of a separate report.
2015-06-03 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.